Goodwin Procter client Mevion Medical Systems recently secured $55 million in equity and debt funding to advance the company’s proton therapy system, MEVION S250. MEVION S250 is the only single-room proton therapy system that is cleared by the United States Food and Drug Administration for clinical use. Funds were raised from existing equity investors and debt financing from Life Sciences Alternative Funding LLC.
Mevion Medical Systems, founded in 2004, is a radiation therapy company and pioneer of modern proton therapy systems dedicated to advancing the treatment of cancer. Mevion is privately held and is based in Littleton, Mass with offices in the United Kingdom and Japan.
Additional information about Mevion and its funding can be found in the company’s press release. The funding was the largest investment among medical device and med-tech-related investments in the second quarter of 2013.